https://rociletinibinhibitor.c....om/cell-occurrence-o
Following the initial phase, participants were given open-label tafolecimab at a dosage of either 150 mg every two weeks or 450 mg every four weeks, for twelve weeks. The percent change from baseline to week 12 in LDL-C levels constituted the primary endpoint. The secondary endpoints evaluated the proportion of participants achieving a 50% reduction in low-density lipoprotein cholesterol (LDL-C) and the proportion a
پسند
تبصرہ
بانٹیں
